Last reviewed · How we verify
Experimental arm (CON):
This drug targets the PD-1 receptor to inhibit cancer cell growth.
This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | Experimental arm (CON): |
|---|---|
| Sponsor | University College, London |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to the PD-1 receptor, the drug prevents cancer cells from evading the immune system, allowing the body's natural defenses to attack and destroy the cancer cells. This leads to an increase in the body's immune response against cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
- Fatigue
- Nausea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental arm (CON): CI brief — competitive landscape report
- Experimental arm (CON): updates RSS · CI watch RSS
- University College, London portfolio CI